linjc16/ctgov huggingface dataset:
Success Rate of Anterior Middle Superior Alveolar (AMSA) Nerve Block in Three Different Sites of Injection

Study Overview
=================
Brief Summary
-----------------
AMSA nerve block injection is targeted anterior superior alveolar nerve and middle superior alveolar nerve branches of infraorbital nerve through nutrient canals. Therefore, central to second premolar teeth of one quadrant can be anesthetized. The aim of the present study was to evaluate the efficacy of AMSA nerve block injection at an anterior and a posterior positions compared to commonly administrated site.

Detailed Description
-----------------
AMSA: Anterior middle superior alveolar

Conditions
-----------------
Anesthesia; Functional

Intervention / Treatment
-----------------
* Procedure: AMSA nerve block injectio


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subject Subjects had all their maxillary teeth from second premolar of one side to the second premolar of another Neither of these teeth was non vital, nor had large restorations, prosthetic crowns, caries, periodontal disease, history of trauma, and hypersensitivity. Exclusion Criteria: Use medications alleviating or altering the pain sensation Allergy to anesthetics Pregnancy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Anterior Site<br>AMSA nerve block injection | Procedure: AMSA nerve block injectio<br>* Sites of injection<br>|
| Experimental: Common Site<br>AMSA nerve block injection | Procedure: AMSA nerve block injectio<br>* Sites of injection<br>|
| Experimental: Posterior Site<br>AMSA nerve block injection | Procedure: AMSA nerve block injectio<br>* Sites of injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulpal anesthesia of central incisor to second premolar by electric pulp tester (EPT) | Each teeth were evaluated by electric pulp tester immediately after injection to 60 minutes every six minutes. Having no reaction to the EPT was the criterion of considering a tooth has been anaesthetized. Anesthesia was considered successful if no reaction to the maximum output for two consecutive tests. | After each injection (base line) to 60 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
local anesthesia, anterior middle superior alveolar nerve, electric pulp tester
Motor Imagery and Action Observation in Respiratory Training

Study Overview
=================
Brief Summary
-----------------
The principal aim of this study was to asses the effects of motor imagery and action observation training on ventilatory and functional capacity through a randomized controlled trial.

Official Title
-----------------
Effects of Motor Imagery and Action Observation on Respiratory Parameters

Conditions
-----------------
Respiratory Function, Motor Imagery, Action Observation Training

Intervention / Treatment
-----------------
* Behavioral: Motor imagery
* Behavioral: Action observation
* Other: Placebo Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 60 Healthy and with no respiratory pathology subjects Exclusion Criteria: Any cognitive impairment that hindered viewing of audiovisual material. Difficulty understanding or communicating. Presence of systemic pathology, Central Nervous System or rheumatic disease. Inadequate understanding of the Spanish language to follow instructions for measuring and treatment. Collaboration of pregnant women. Underage subject

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motor imagery<br>Motor imagery of inspiratory and expiratory exercises, 10 series of 1 minute. | Behavioral: Motor imagery<br>* Mental imagery of respiratory exercises<br>|
| Experimental: Action observation<br>Action observation of inspiratory and expiratory exercises, 10 series of 1 minute. | Behavioral: Action observation<br>* Action observation of respiratory exercises<br>|
| Placebo Comparator: Placebo Observation<br>Placebo visualization of nature video, 10 minutes. | Other: Placebo Intervention<br>* Placebo observation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Forced vital capacity physiological parameter | With spirometry | Preintervention and postintervention (after the 10 minutes intervention) | 
| Change from FEV1 physiological parameter | With spirometry | Preintervention and postintervention (after the 10 minutes intervention) |
Assessing the Feasibility of Integrating Ear Acupuncture Into the Aeromedical Evacuation System From RAB to AAFB

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is twofold: 1) to test the feasibility of integrating a simple bilateral ear acupuncture procedure (Auricular Stimulation Procedure - ASP) into the standard care delivered in the Aeromedical Evacuation system and 2) to observe and document any changes in pain scores and in-flight related symptoms and factors (e.g. sinus block/pain, ear block pain, nausea/air sickness) typically monitored during transportation of wounded warriors from Ramstein Air Base (RAB) to Andrews Air Force Base (AAFB).

Official Title
-----------------
The Feasibility of Integrating Ear Acupuncture for Pain in Patients Being Transported Via the Aeromedical Evacuation System From Ramstein Air Base to Andrews AFB, Maryland USA: An Observational Study

Conditions
-----------------
Musculoskeletal Pain

Intervention / Treatment
-----------------
* Device: Ear acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or over NRS Pain rating > 0 Military beneficiaries undergoing aeromedical evacuation from RAB to AAFB Exclusion Criteria: Medically unstable or otherwise unable to participate including those with the inability to consent Allergy to metals Ear trauma Sepsis Unhealed wounds on the ears Piercing or scar tissue in any of the ear acupuncture point areas Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pain Patients<br> | Device: Ear acupuncture<br>* Ear acupuncture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain |  | March 2013 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, acupuncture
Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to address the comparative effectiveness and harm of the therapeutics frequently given to pregnant women and their young infants including antibiotics, tocolytic agents, non-steroidal anti-inflammatory drugs, H2 blockers, and steroids. Our overall hypothesis is that the use of an existing electronic medical record with additional resources for precise data collection and 18 month follow up will successfully address current knowledge gaps in therapeutic effectiveness and relative therapeutic harm. We will use an existing electronic medical record into which detailed healthcare information is entered for over 100,000 newborns each year. These infants will comprise the Source Cohort. Nested within that database, we will prospectively enroll 10% of the population (10,000 newborns) as the Follow-Up Cohort. The current electronic medical record for the Source Cohort does not capture therapeutic dosing with sufficient precision to conduct comparative effectiveness research sufficient to change medical practice. The proposed research will: 1) ensure accurate data collection through electronic monitoring and real-time quality assurance evaluation in the Source Cohort; and 2) conduct 18 months post-hospital follow-up for neurologic outcomes and disability for the Follow-Up Cohort. We will complete assessments of neurologic outcomes and disability using an interactive web-based system, mail, telephone follow up, and in-person examination.

Official Title
-----------------
Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

Conditions
-----------------
Gastroesophageal Reflux, Presumed Sepsis, Patent Ductus Arteriosus, Chronic Lung Disease, Neurodevelopmental Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to the a Pediatrix Medical Group NICU <=5 days of life likely to follow-up at 18 months adjusted age Exclusion Criteria: failure to consent

Ages Eligible for Study
-----------------
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Extremely Premature Infants<br>< 30 weeks gestation (N=5000) | |
| Premature Infants<br>30-36 weeks gestation (N=2000) | |
| Hospitalized Term Infants<br>>=37 weeks gestation (N=2000) | |
| Healthy Term Infants<br>>=37 weeks gestation (N=1000) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
therapeutics, safety, maternal, neonatal
Comparative Study of QuietCare

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to examine the efficacy and safety of QuietCare in a randomized, open study in elderly subjects living in assisted/ independent living facilities for 6 months.

Official Title
-----------------
Randomized Comparative Study of QuietCare (Motion Sensor System) in Elderly Subjects Living in Assisted/ Independent Living Facilities

Conditions
-----------------
Elderly People, Living Alone in a Residence With Care Giver

Intervention / Treatment
-----------------
* Device: QuietCare


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ability to move independently or by using a walker (without assistance) inside residents using a single room, age 65 or older, of either sex Exclusion Criteria: people who use wheel chairs, people who are bed-ridden

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: QuietCare<br>QuieCare system installed | Device: QuietCare<br> <br> * Other names: passive monitoring system using infrared;|
| No Intervention: control<br>no system installed | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in score of Care Service Quetionnaire | improvement in care level assessment improvement in care plannning improvement in communication among staff improvement in communication with residents and their family | The observation period is 6 months. | 
| Time required for staff to respond to events |  | The observation period is 6 months. | 
| Incidence of falls |  | The observation period is 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fee for medical and nursing care treatments |  | The observation period is 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
elderly, fall, acute illness, care giver
US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors

Study Overview
=================
Brief Summary
-----------------
A retrospective evaluation of soft tissue tumors that have undergone core needle biopsy with US guidance (US-CNB)

Detailed Description
-----------------
The present study is designed to be the first step in the creation of an interdisciplinary platform collecting data on patients and procedures to provide a predictive tool to help physicians in the management of patients affected by a soft tissue lesion. The primary aim of our work is to evaluate the diagnostic yield of US-CNB. The secondary aim is to exploit all the imaging data conventionally available at a Sarcoma Center before a biopsy on a soft tissue mass, to build a multiparametric model and score of prediction of malignancy, and eventually of biological behavior - grading.

Official Title
-----------------
Diagnostic Yield of Ultrasound-Guided Needle Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors

Conditions
-----------------
Soft Tissue Neoplasm, Soft Tissue Sarcoma, Soft Tissue Mass, Soft Tissue Lesion

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergone US-CNB for soft tissue lesions at the Rizzoli Orthopaedic Institute Exclusion Criteria: Patients whose histological diagnosis is not available
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic yield | Diagnostic yield will be defined as the number of diagnostic core needle biopsies divided by the total number of core needle biopsies. A diagnostic yield > 94% will be considered sufficient to produce a sample to reach the histological diagnosis. | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prediction of malignancy | To determine which imaging features and biomarkers correlates with malignancy and biological behavior of soft tissue masses. | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
US-CNB, Soft Tissue Mass, Soft Tissue Sarcoma, Soft Tissue Neoplasm, Soft Tissue Lesion
Plasma and Intrapulmonary Concentrations Study of WCK 5222

Study Overview
=================
Brief Summary
-----------------
This is a Phase 1, multiple dose, open-label pharmacokinetic study in healthy adult male and female subjects.

Official Title
-----------------
A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 5222 (Cefepime and Zidebactam) in Healthy Adult Human Subjects

Conditions
-----------------
PHA1A

Intervention / Treatment
-----------------
* Drug: FEP-ZID


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index (BMI) greater than or equal to18.5 and less than or equal to 30 (kg per m2) and weight between 55.0 and 100.0 kg (both inclusive). Medical history without any major pathology as judged by the Investigator. Forced expiratory volume in 1 second (FEV1) of at least 70% of predicted value at screening. Exclusion Criteria: History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal,endocrine, immunologic, dermatologic, neurological, or psychiatric disease. Positive alcohol breath test or urine drug screen test at screening or confinement. Current use or has used tobacco or nicotine containing products 6 month prior to screening. Positive testing for HIV, Hepatitis B or Hepatitis C. History or presence of alcohol or drug abuse within the 2 years prior to screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FEP-ZID via intravenous<br>total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen | Drug: FEP-ZID<br>* A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentrations of cefepime (FEP) and zidebactam in epithelial lining fluid (ELF) |  | Day 3 | 
| concentrations of cefepime (FEP) and zidebactam in alveolar macrophage (AM) |  | Day 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse event reported |  | Day 3 | 
| number variation noted in 12-lead electrocardiogram |  | Day 3 |
Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity

Study Overview
=================
Brief Summary
-----------------
The researchers will investigate if brain insulin action influences peripheral insulin sensitivity in healthy humans.

Official Title
-----------------
Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity

Conditions
-----------------
Insulin Sensitivity

Intervention / Treatment
-----------------
* Drug: human insulin as nasal spray
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI < 28 kg/m2 normal HbA1c healthy volunteers Exclusion Criteria: Heparin induced thrombocytopenia (HIT) metal implants cardial diseases anemia patients taking any kind of drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: insulin nasal spray<br>160 Units of human insulin as nasal spray | Drug: human insulin as nasal spray<br> <br> |
| Placebo Comparator: Placebo nasal spray<br>Nasalspray containing placebo solution | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity as measured by clamp | We will measure insulin sensitivity by hyperinsulinemic euglycemic clamp before and after nasal spray application. We will compare the post-spray insulin sensitivity between the two condition (insulin nasal spray vs placebo nasal spray). Furthermore, we will compare insulin sensitivity before and after nasal insulin application. | 45 minutes to 120 minutes post nasal spray | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Autonomous nervous system activity | Activity of the autonomous nervous system will be estimated by heart rate variability in ECG. We will compare the post-spray autonomous nervous system activity between the two condition (insulin nasal spray vs placebo nasal spray). Furthermore, we will compare autonomous nervous system activity before and after nasal insulin application. | 45 to 120 minutes post spray | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
whole body insulin sensitivity, insulin action in the brain
Validation of the San Francisco Syncope Rule

Study Overview
=================
Brief Summary
-----------------
This study was designed to validate the San Francisco Syncope Rule. This set of rules was derived by Quinn et. al. to help guide the treatment of patients evaluated in the Emergency Department who had an episode of syncope (passed out) or near syncope (almost passed out). A rule that considers patients with an abnormal ECG, a complaint of shortness of breath, hematocrit less than 30%, systolic blood pressure less than 90 mm Hg, or a history of congestive heart failure was shown predict with a good degree of accuracy which patients would have an adverse event and require admission.

Detailed Description
-----------------
This study was designed to validate the San Francisco Syncope Rule. This set of rules was derived by Quinn et. al. to help guide the treatment of patients evaluated in the Emergency Department who had an episode of syncope or near syncope. A rule that considers patients with an abnormal ECG, a complaint of shortness of breath, hematocrit less than 30%, systolic blood pressure less than 90 mm Hg, or a history of congestive heart failure was shown predict with a good degree of accuracy which patients would have an adverse event/serious outcome and require admission. Serious outcomes include the following: death,myocardial infarction, arrhythmia, pulmonary embolism, stroke, subarachnoid hemorrhage, significant hemorrhage, or any condition causing a return ED visit and hospitalization for a related event. In Quinn's derivation trial, the sensitivity of the rule was 96%.

Official Title
-----------------
Validation of the San Francisco Syncope Rule

Conditions
-----------------
Syncope, Near Syncope

Intervention / Treatment
-----------------
* Procedure: Application of the San Francisco Syncope Rule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute syncope or near syncope as a reason for the ED visit Exclusion Criteria: Altered mental status, alcohol or illicit drug-related loss of consciousness, Definite seizure, Transient loss of consciousness caused by head trauma

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Application of the San Francisco Syncope Rule|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Syncope, Near syncope, San Francisco Syncope rule